At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 104 enrolled
Drug / intervention
pregabalindrug
Likely dose
pregabalin 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Sep 15, 2010·Updated Jan 28, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin for Spinal Cord Diseases and 3 related conditions. Completed, enrolled 104 participants across 26 sites.
Detailed Summary
The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Diseases, Spinal Cord Injuries, Neuralgia, Pain
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedSep 2010
Primary CompletionMar 2012
TodayJul 2026
First PostedSep 15, 2010
Enrollment StartSep 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.8 years ago
Interventions
pregabalindrug
Pregabalin capsules taken twice a daily (150-600mg/day)